Current Research and Development
CICADEA BIOTECH
Novel Biomarker for Kidney Cancer
Cicadea Biotech is developing the first urine test for kidney cancer detection. Kidney cancer affected around 81,800 patients in 2023 in the US. Early-stage cancer patients may not present with symptoms and yet this is the critical phase for surgery success (93% survival rate if caught early). Thus, kidney cancer is known as a ‘silent killer’ because malignancy may not be detected until large disruptive tumors are present or metastasis cause symptoms. There is a significant need for a general preventive screening method for kidney cancer. The Cicadea test, a non-invasive system using a novel biomarker, will help identify patients at an early stage of cancer before symptom onset or suspicion of malignancy. By finding early-stage tumors, this test could greatly improve patient outcomes.
How We Can Help
Send us your samples or names of pathogens you want us to identify. We will analyze the associated DNA sequence and develop PCR based assays for you in a timely fashion. We can also run the PCR assays on your samples and send you the final testing results.
What we need from you:
- Names of the organisms that you want to detect or identify
- Test samples for identification or detection
Please contact us to discuss more details regarding specific requirements.